Mediterranean diet intervention may not improve breast cancer prognosis in high-risk patients

In a recent study published in Clinical Cancer Research, researchers discuss the results of a randomized controlled trial to explore the impact of diet on breast cancer recurrence.

Study: The effect of Diet on Breast Cancer recurrence: the DIANA-5 randomized trial. Image Credit: 9nong / Shutterstock.com

Background

Recent advancements in breast cancer treatment have significantly increased the number of cancer survivors worldwide. In the United States, Canada, Australia, Japan, and many European countries, the five-year survival rate of breast cancer has reached 85-90%; however, the risk of death from breast cancer is still high among high-risk women with certain comorbidities.

Epidemiological evidence indicates that obesity, metabolic syndrome, and high blood levels of glucose, insulin, and testosterone are major risk factors for breast cancer recurrence among women, even after menopause.

Nevertheless, several studies have reported that the metabolic and hormonal risk factors associated with breast cancer recurrence can be mitigated by adopting a healthy diet and lifestyle. The Mediterranean diet, which primarily includes plant-based food products, is known to reduce the risk of metabolic syndrome and improve body composition, insulin sensitivity, glucose metabolism, and blood lipid profiles.   

In the current randomized controlled dietary intervention DIet and Androgen 5 (DIANA-5) trial, researchers investigate the effect of the macro-Mediterranean® diet, which involves the Mediterranean diet in combination with increased phytoestrogen intake, on breast cancer recurrence. Previous DIANA trials have reported the benefits of the macro-Mediterranean® diet in reducing insulin resistance, testosterone levels, and other factors associated with metabolic syndrome.

Study design

The current study included 1,542 breast cancer patients who underwent surgery for invasive breast cancer within the previous five years. All study participants were at an increased risk of breast cancer recurrence because of having estrogen receptor (ER)-negative breast cancer, metabolic syndrome, or high blood levels of insulin or testosterone.

Study participants were randomly assigned to the macro-Mediterranean dietary intervention group or control group. The intervention consisted of kitchen courses, monthly community meals, and dietary and physical activity recommendations.

Vegetables, fruits, nuts, olive oil, fish, whole grains, legumes, and soy products were among the recommended foods. Comparatively, refined foods, sugary foods, potatoes, red meat, processed meat, dairy products, and alcohol were not recommended. A compliance dietary index was defined by the difference between intake of recommended and non-recommended foods.  

Participants from both intervention and control groups received general recommendations for cancer prevention.

Important observations

A total of 769 and 773 high-risk women with breast cancer were assigned to the intervention and control groups, respectively, and monitored for five years. In both groups, participants received a breast cancer diagnosis at an average of 1.8 years before enrollment.

In terms of pathological variables such as tumor type, size, and grade, nodal metastasis, and hormone receptor status at the time of diagnosis, participants from both groups had comparable characteristics.

The analysis of 24-hour food frequency reports at baseline revealed a similar intake of recommended foods by both groups. However, a slightly higher intake of non-recommended foods and a lower dietary index were observed in the control group.  

Both groups exhibited significant improvements in anthropometric and metabolic parameters after one year. However, the changes in all parameters were comparatively higher in the intervention group.

A significantly higher reduction in body weight, body mass index (BMI), waist circumference, glucose level, triglyceride level, and metabolic syndrome parameters was observed in the intervention group as compared to the control group.

A significantly increased intake of recommended foods and reduced intake of non-recommended foods was observed in the intervention group as compared to the control group at the one-year follow-up visit. Similarly, the intervention group was associated with a significant improvement in dietary index than the control group throughout the follow-up.

Breast cancer incidence

Recurrence of breast cancer was observed in 95 and 98 participants from the intervention and control groups, respectively, over the five-year follow-up period. Additionally, both groups were associated with a similar incidence of distant metastasis. Survival rates without recurrence were also comparable between the two groups.

Study participants with a high dietary index were associated with a significantly reduced incidence of new breast cancer events than those with a low dietary index.  

Significance

The consumption of the Mediterranean diet in combination with phytoestrogen does not appear to reduce the risk of breast cancer recurrence among high-risk women. However, a better prognosis of breast cancer has been observed among women with higher compliance with dietary recommendations.

Journal reference:
  • Berrino, F., Villarini, A., Gargano, G., et al. (2023). The effect of Diet on Breast Cancer recurrence: the DIANA-5 randomized trial. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-23-1615/729615
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha Dutta. (2023, October 22). Mediterranean diet intervention may not improve breast cancer prognosis in high-risk patients. News-Medical. Retrieved on December 23, 2024 from https://www.news-medical.net/news/20231020/Mediterranean-diet-intervention-may-not-improve-breast-cancer-prognosis-in-high-risk-patients.aspx.

  • MLA

    Dutta, Sanchari Sinha Dutta. "Mediterranean diet intervention may not improve breast cancer prognosis in high-risk patients". News-Medical. 23 December 2024. <https://www.news-medical.net/news/20231020/Mediterranean-diet-intervention-may-not-improve-breast-cancer-prognosis-in-high-risk-patients.aspx>.

  • Chicago

    Dutta, Sanchari Sinha Dutta. "Mediterranean diet intervention may not improve breast cancer prognosis in high-risk patients". News-Medical. https://www.news-medical.net/news/20231020/Mediterranean-diet-intervention-may-not-improve-breast-cancer-prognosis-in-high-risk-patients.aspx. (accessed December 23, 2024).

  • Harvard

    Dutta, Sanchari Sinha Dutta. 2023. Mediterranean diet intervention may not improve breast cancer prognosis in high-risk patients. News-Medical, viewed 23 December 2024, https://www.news-medical.net/news/20231020/Mediterranean-diet-intervention-may-not-improve-breast-cancer-prognosis-in-high-risk-patients.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer